To highlight the limitations of traditional glaucoma treatment with topical drops and advocate for earlier interventional approaches to improve patient outcomes.
Approach:
Interventional Glaucoma: Emphasizes the need for earlier intervention in glaucoma management to improve patient outcomes and quality of life.
Challenges with Topical Therapy: Discusses the high rates of nonadherence to prescribed drop therapy and its consequences on disease progression.
Minimally Invasive Glaucoma Surgery (MIGS): Introduces MIGS as a safer alternative to traditional surgery, allowing for earlier intervention.
Key Findings:
90% of patients do not adhere to their prescribed drop schedule according to the IRIS Registry Study.
50% of patients stop using their drops within 6 months as reported in the Market Scope Survey.
Topical medications are effective but often lead to inconsistent IOP control, as noted in various studies.
Minimally invasive procedures like selective laser trabeculoplasty (SLT) show promising results in maintaining IOP control with fewer complications, supported by the LiGHT trial.
Interpretation:
The reliance on topical drops for glaucoma management is problematic due to high nonadherence rates, leading to worse long-term outcomes. Early intervention with MIGS and sustained-release drug delivery systems may provide better control and quality of life for patients.
Limitations:
The article does not provide specific data on the long-term outcomes of interventional glaucoma approaches compared to traditional methods, as noted in the IRIS Registry.
Potential biases in the studies cited may affect the generalizability of the findings, as discussed in the Market Scope Survey.
Conclusion:
A shift towards interventional glaucoma strategies is necessary to address the challenges of adherence in glaucoma care.
Is There a Role for SLT After MIGS? A practical framework for patient selection and clinical decision-making when intraocular pressure rises after minimally invasive glaucoma surgery.
Ophthalmologists caring for adults with this condition may encounter persistent inflammation, treatment dependence, and the cumulative ocular effects of childhood disease.
